FDA expands label for Teva's Azilect; Ackman says he 'followed the rules';

@FiercePharma: Top-read on FP this weekend: AbbVie readies production in anticipation of hep C treatment approval. Story | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? Check out this discussion FiercePharma's LinkedIn group: Conversation | Follow @TracyStaton

@EricPFierce: ICYMI Friday: The #FDA and #EMA see the world of inspections differently and Ranbaxy case shows that. Article | Follow @EricPFierce

@CarlyHFierce: Could automating production solve #India's #manufacturing problems? More | Follow @CarlyHFierce

@JustinHFierce: Because pigs, apparently, get all the action: $NVS out with fast-acting Florvio to combat swine respiratory disease. More | Follow @JustinHFierce

> The FDA has expanded the label for Teva's ($TEVA) Azilect for treatment across all stages of Parkinson's disease. Release

> Valeant's takeover partner ($VRX), Bill Ackman, says he followed the rules with his Allergan ($AGN) investment. Report

> The FDA has approved Valeant's Jublia for toenail fungus. Story

> The biggest spike in ADHD medication is among women between the ages of 19 and 34, a recent report says. More

> Inflammation may help explain the link between depression and diabetes. More

> Psoriasis negatively impacts the qualify of life of both patients and the people who live with them, a new study shows. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Kleiner Perkins, TPG-backed heart transplant monitor company files for $50M IPO. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI Friday: Ethicist: Recycling medical equipment from the dead OK. Story | Follow @VarunSaxena2

@MichaelGFierce: Singapore team designs nanotechnology glaucoma treatment for sustained release. FierceDrugDelivery article | Follow @MichaelGFierce

@EmilyWFierce: New test that pinpoints multiple genes in a tumor could replace companion Dx as a tool for diagnosing. Reuters article | Follow @EmilyWFierce

> Devicemakers stash money abroad for tax purposes, possibly fueling deals overseas. Article

> Kamra gets FDA panel OK, but safety concerns nag. Story

> Dutch company develops 3-D printing process for lenses and glasses. More

> New MRI technique could speed up diagnosis for traumatic brain injury. Report

Biotech News

@FierceBiotech: ICYM @EricPFierce's #ASCO14 chat with @JonEPVantage, review the recap here. Chat | Follow @FierceBiotech

@JohnCFierce: $MRK's ability to charge into a triple-drug study and get it through the clinic will say a lot about the R&D culture under Perlmutter. | Follow @JohnCFierce

@DamianFierce: $MRK's $3.85B $IDIX deal is a roughly 340% premium on Friday's close. Release | Follow @DamianFierce

@EmilyMFierce: Antibiotic Resistance Revitalizes Century-Old Virus Therapy. More from Scientific American | Follow @EmilyMFierce

> Biogen Idec racks up another blockbuster FDA approval, this time for hemophilia. Article

> IPO-hopeful Kite Pharma inks an NIH licensing deal on hot TCR tech. Story

> Ackman says Allergan shareholders are on board for Valeant's $53B takeover. Report

> Merck scoops up troubled Idenix's hep C drugs in $3.85B buyout. News

CRO News

> CROs unite to kick-start a biotech's pipeline. Report

> Parexel eyes a $150M share buyback. Item

> Celerion moves into Singapore amid Asian expansion. Article

> InVentiv signs on to market 3-D printed drugs. Story

> Bristol-Myers deepens its ties to Biocon's CRO and Indian R&D. More

Biotech IT News

> FDA opens adverse-event data to app developers in first wave of openFDA. More

> EU ombudsman probes link between AbbVie case and trial transparency U-turn. Story

> Venter Institute wins $25M NIH grant to apply sequencing tech to infectious diseases. Report

> CamCog adds iPad trial tech for cognitive safety, abuse potential. Item

> Lilly, Novartis and Pfizer join with Broad Institute for bioinformatics challenge. Article

And Finally... Oral contraceptives may impact what traits women desire in an imaginary mate. More

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.